October is both Pancreatic Cancer and Breast Cancer Awareness Month.
A new approach to treating pancreatic cancer is progressing to the next step in making available to more patients. After results from a small study, a phase 2 trial has now opened to test the effectiveness of using an mRNA vaccine to fight one of the deadliest cancers.
The new trial is investigating whether this therapeutic vaccine reduces the risk of pancreatic cancer returning after the tumor is removed by surgery. The study will enroll about 260 patients at Memorial Sloan Kettering Cancer Center and nearly 80 sites around the world.
The trial is open to people newly diagnosed with pancreatic cancer who have not yet had surgery or other treatment such as chemotherapy, immunotherapy or radiation therapy and who fit other specific criteria.
to learn more about enrolling in the trial at MSK, call Patient Access Services at 332-266-8811.
